An innovative colon inflammation-targeting platform for ulcerative colitis treatment
5 affiliations
- 1Division of Gastroenterology and Hepatology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.
- 2Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA.
- 3Department of Oncology, Sidney Kimmel Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.
- 4The Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD 21231, USA.
- 5Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.
Abstract
The therapeutic options for patients with inflammatory bowel disease (IBD) have recently expanded substantially. Tofacitinib, an oral small-molecule inhibitor of Janus kinase (JAK), recently FDA approved for ulcerative colitis, represented a paradigm shift in a field previously dominated by biologics. Tofacitinib, however, carries a black box warning for major adverse cardiovascular events, an elevated risk of malignancies, risk of blood clots, and pulmonary embolism. In addition, tofacitinib is avoided in pregnancy and used with caution in women of child bearing age due to potential risks to the developing fetus. Notably, these potential complications are all due to the systemic distribution of tofacitinib. To address these issues, we developed Lipo-tm-HA, a liposomal platform incorporating mannitol (m) and hyaluronic acid (HA) for targeting tofacitinib (t) to the inflamed colon. We characterized Lipo-tm-HA and have shown that it (i) remains stable in gastric conditions due to HA coating, (ii) adheres to transferrin in inflamed mucosa due to its negative charge, and (iii) enhances macrophage uptake through mannose receptor-mediated endocytosis. Due to targeting, we show that a single oral administration of Lipo-tm-HA at a dose of 10 milligrams per kilogram is superior in efficacy compared with daily treatment with free tofacitinib in a dextran sodium sulfate-induced colitis model. Collectively, our innovative formulation will enable colonic inflammation targeting, reduce systemic exposure, and allow administration of decreased doses.
Related
- Fagopyrum cymosum Extract Improves Mitochondrial Function and Reduces Colonic Inflammation in Ulcerative Colitis by Targeting the PI3K/Akt/FOXO3A Pathway
- Microemulsion co-delivering vitamin A and vitamin E as a new platform for topical treatment of acute skin inflammation
- Potential role of resveratrol in abdominal cocoon syndrome: targeting inflammation, oxidative stress, and fibrosis via food-derived bioactive compounds resveratrol for treatment of abdominal cocoon syndrome
- Discovery of a potent covalent inhibitor for the treatment of sepsis targeting DNAJC9: Identification of a druggable target for inflammation.
- Inflammation-Masked Sporadic Colorectal Cancer Detected After Remission Induction in Elderly-Onset Ulcerative Colitis
BibTeX
@article{islam2026innovative,
title = {{An innovative colon inflammation-targeting platform for ulcerative colitis treatment}},
author = {Waliul Islam and Haiming Chen and Ling Li and Kevan J. Salimian and Florin M. Selaru},
journal = {Science Advances},
year = {2026},
month = oct,
doi = {10.1126/sciadv.aeb1963},
url = {https://www.science.org/doi/10.1126/sciadv.aeb1963},
note = {CC BY},
}
RIS
TY - JOUR
TI - An innovative colon inflammation-targeting platform for ulcerative colitis treatment
AU - Waliul Islam
AU - Haiming Chen
AU - Ling Li
AU - Kevan J. Salimian
AU - Florin M. Selaru
PY - 2026
DA - 2026/10/23
JO - Science Advances
DO - 10.1126/sciadv.aeb1963
UR - https://www.science.org/doi/10.1126/sciadv.aeb1963
AB - The therapeutic options for patients with inflammatory bowel disease (IBD) have recently expanded substantially. Tofacitinib, an oral small-molecule inhibitor of Janus kinase (JAK), recently FDA approved for ulcerative colitis, represented a paradigm shift in a field previously dominated by biologics. Tofacitinib, however, carries a black box warning for major adverse cardiovascular events, an elevated risk of malignancies, risk of blood clots, and pulmonary embolism. In addition, tofacitinib is avoided in pregnancy and used with caution in women of child bearing age due to potential risks to the developing fetus. Notably, these potential complications are all due to the systemic distribution of tofacitinib. To address these issues, we developed Lipo-tm-HA, a liposomal platform incorporating mannitol (m) and hyaluronic acid (HA) for targeting tofacitinib (t) to the inflamed colon. We characterized Lipo-tm-HA and have shown that it (i) remains stable in gastric conditions due to HA coating, (ii) adheres to transferrin in inflamed mucosa due to its negative charge, and (iii) enhances macrophage uptake through mannose receptor-mediated endocytosis. Due to targeting, we show that a single oral administration of Lipo-tm-HA at a dose of 10 milligrams per kilogram is superior in efficacy compared with daily treatment with free tofacitinib in a dextran sodium sulfate-induced colitis model. Collectively, our innovative formulation will enable colonic inflammation targeting, reduce systemic exposure, and allow administration of decreased doses.
SN - 2375-2548
ER -